Geratherm Medical (GME) AI Stock Analysis

• Market Cap: €18.24M
• Dividend Yield: 2.99%
• Average Volume (3M): 1.63K
• Price to Earnings (P/E): 10.3
• Beta (1Y): 0.24
• Revenue Growth: -23.48%
• EPS Growth: N/A
• Country: DE
• Employees: 179
• Sector: Healthcare
• Sector Strength: 45
• Industry: Medical - Devices
• EPS (TTM): -0.03
• Shares Outstanding: 5,444,998
• 10 Day Avg. Volume: 3,778
• 30 Day Avg. Volume: 1,625
• PEG Ratio: N/A
• Price to Book (P/B): N/A
• Price to Sales (P/S): N/A
• P/FCF Ratio: N/A
• Enterprise Value/Market Cap: N/A
• Enterprise Value/Revenue: N/A
• Enterprise Value/Gross Profit: N/A
• Enterprise Value/Ebitda: N/A
• 1Y Price Target: €3.50
• Price Target Upside: 4.48% Upside
• Rating Consensus: Hold
• Number of Analyst Covering: 0

• Rating: 67 Neutral
• Price Target: €3.50 ▲(4.48% Upside)

Geratherm Medical's overall stock score is driven by its stable financial position and attractive valuation. While technical indicators suggest a cautious approach, the low P/E ratio and strong dividend yield provide a solid investment case. Continued focus on improving revenue growth and operational efficiency will be key for future performance.

Geratherm Medical Business Overview & Revenue Model

Company Description

Geratherm Medical AG operates as a medical technology company in Germany. It operates through Healthcare Diagnostic, Respiratory, Cardio/Stroke, and Medical Warming Systems segments. The Healthcare Diagnostic segment provides clinical thermometers; blood pressure monitors; and self-test diagnostic products for women, including pregnancy tests, chlamydia tests, urinary tract infections, diverse ovulation test solutions, and pH tests. The Respiratory segment develops and manufactures products primarily for pulmonary and cardiopulmonary function diagnostics. The Medical Warming Systems segment offers MRI-compatible incubators for premature and newborn infants under the LMT brand. The Cardio/Stroke segment offers stroke risk analysis products for the detection of atrial fibrillation. The company markets its products through pharmacies, hospitals, and clinics. It exports its products to approximately 60 countries. The company was founded in 1990 and is headquartered in Geschwenda, Germany.

How the Company Makes Money

Geratherm Medical generates revenue through the sale of its medical devices and diagnostic products to hospitals, clinics, and retail pharmacies. The company has established key revenue streams through direct sales, distribution agreements, and partnerships with healthcare providers and organizations. Additionally, GME focuses on expanding its market presence in emerging economies and leverages research and development to innovate and introduce new products, thus enhancing its competitive edge and driving sales growth.

Geratherm Medical Financial Statement Overview

Summary

Geratherm Medical shows a stable financial position with a strong equity base and improved cash flow management. However, challenges in revenue growth and profitability, along with fluctuating margins, indicate areas for improvement.

Income Statement

Geratherm Medical's income statement shows a mixed financial performance. The gross profit margin improved significantly in 2024, indicating better cost management. However, the revenue has been declining since 2020, suggesting challenges in sales growth. The net profit margin decreased in 2024, reflecting pressure on bottom-line profitability. EBIT and EBITDA margins have fluctuated, showing inconsistency in operational efficiency.

Balance Sheet

The balance sheet reveals a strong equity position, with a high equity ratio indicating financial stability. The debt-to-equity ratio has decreased, reflecting reduced leverage risk. However, the return on equity has been low, signaling potential inefficiencies in generating returns from shareholders' equity.

Cash Flow

The cash flow analysis shows an improvement in free cash flow in 2024, indicating better cash management. The operating cash flow to net income ratio is strong, suggesting good cash generation capability. However, fluctuations in free cash flow in prior years highlight potential volatility in cash flow stability.

Breakdown	TTM	Dec 2024	Dec 2023	Dec 2022	Dec 2021	Dec 2020
Income Statement
Total Revenue	18.31M	20.43M	22.30M	25.85M	24.64M	27.47M
Gross Profit	13.39M	12.78M	7.62M	6.38M	16.32M	17.60M
EBITDA	1.61M	2.95M	4.18M	3.37M	2.20M	4.35M
Net Income	-830.50K	705.17K	1.11M	1.02M	332.65K	2.05M
Balance Sheet
Total Assets	33.65M	28.54M	35.72M	38.38M	34.56M	35.99M
Cash, Cash Equivalents and Short-Term Investments	6.33M	9.64M	7.74M	10.89M	6.47M	10.26M
Total Debt	6.57M	3.28M	7.23M	9.29M	9.32M	10.14M
Total Liabilities	12.29M	7.71M	13.11M	14.64M	15.93M	16.07M
Stockholders Equity	21.17M	21.02M	22.33M	22.34M	18.52M	20.30M
Cash Flow
Free Cash Flow	-696.00K	1.23M	-212.00K	-133.00K	-353.00K	1.14M
Operating Cash Flow	33.00K	1.87M	1.43M	2.61M	917.00K	3.92M
Investing Cash Flow	-1.78M	3.82M	-2.31M	-985.00K	3.00K	-3.79M
Financing Cash Flow	-3.29M	-2.69M	-2.83M	4.75M	-3.52M	684.00K

Geratherm Medical Technical Analysis

• Technical Analysis Sentiment: Positive
• Last Price: 3.35
• 50DMA: Positive
• 100DMA: Positive
• 200DMA: Positive
• MACD: Negative
• RSI: Negative
• STOCH: Neutral

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For DE:GME, the sentiment is Positive. The current price of 3.35 is above the 20-day moving average (MA) of 3.10, above the 50-day MA of 3.11, and above the 200-day MA of 3.22, indicating a bullish trend. The MACD of 0.02 indicates Negative momentum. The RSI at 70.82 is Negative, neither overbought nor oversold. The STOCH value of 62.95 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for DE:GME.

Geratherm Medical Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
GME	67 Neutral	€18.24M	10.28	8.35%	2.99%	-23.48%	―
AAQ1	47 Neutral	€22.25M	-4.79	-34.70%	―	-0.59%	24.03%
Sector *	51 Neutral	$7.86B	-0.30	-43.30%	2.27%	22.53%	-2.21%